Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics Inc    AIMT

AIMMUNE THERAPEUTICS INC (AIMT)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
29.34(c) 29.11(c) 29.6(c) 29.06(c) 29.24(c) Last
334 033 278 741 244 301 287 460 295 874 Volume
+2.30% -0.78% +1.68% -1.82% +0.62% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -198 M
Net income 2018 -197 M
Finance 2018 92,2 M
Yield 2018 -
Sales 2019 40,6 M
EBIT 2019 -159 M
Net income 2019 -156 M
Finance 2019 42,2 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 41,4x
Capitalization 1 720 M
More Financials
Company
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies.Its portfolio includes the characterized oral desensitization immunotherapy system.The company was founded on... 
Sector
Pharmaceuticals
Calendar
11/06Earnings Release
More about the company
Surperformance© ratings of Aimmune Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on AIMMUNE THERAPEUTICS INC
06/19AIMMUNE THERAPEUTICS INC : Breakfast Technical Briefing on Alkermes and Three Ot..
AC
06/13AIMMUNE THERAPEUTICS : Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
AQ
06/13AIMMUNE THERAPEUTICS : Appoints Dr. Jayson Dallas as CEO
AQ
06/12AIMMUNE THERAPEUTICS : New chief at Aimmune
AQ
06/11AIMMUNE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulati..
AQ
06/11AIMMUNE THERAPEUTICS : Appoints Dr. Jayson Dallas as CEO
BU
06/01AIMMUNE THERAPEUTICS INC : Wired News - Aimmune Therapeutics Presents Data from ..
AC
06/01AIMMUNE THERAPEUTICS : Announces New Pan-European Study Showing Significant Psyc..
AQ
05/31AIMMUNE THERAPEUTICS : Announces New Pan-European Study Showing Significant Psyc..
AQ
05/30AIMMUNE THERAPEUTICS : Announces New Pan-European Study Showing Significant Psyc..
BU
More news
Sector news : Specialty & Advanced Pharmaceuticals
07/19AMGEN : and Cedars-Sinai in Collaboration for 'Health-Care Quality'
DJ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK AND : Announces Plan to Lower Prices of Some Drugs
DJ
07/19JOHNSON & JOHNSON : Women who sued J&J declare victory after $4.69 billion talc ..
RE
07/19Barclays Poaches Senior Health-Care Banker From Deutsche Bank
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
07/19Want automatic email alerts for $PRT $USX $AIMT $YGE $CRUS? Subscribe to Mark.. 
07/17BidaskClub Upgrades Aimmune Therapeutics $AIMT to “Hold”  
06/29Speculative stock, serious goals? 's getting the latest on 's allergy-treatin..
2
06/26Aimmune Therapeutics $AIMT Lowered to Sell at BidaskClub  
06/25Aimmune Therapeutics $AIMT Downgraded by BidaskClub to Sell  
More tweets
Qtime:40
News from SeekingAlpha
07/19AIMMUNE : Societal Benefits 
07/01SA INTERVIEW : Event-Driven Investing With Panther Investments 
06/21Market Keeps Rewarding Growth - Cramer's Mad Money (6/20/18) 
06/19INSTITUTIONAL TOP IDEAS : Great Point Partners 
06/13Aimmune Therapeutics (AIMT) Presents At 38th Nasdaq Investor Conference - Sli.. 
Chart AIMMUNE THERAPEUTICS INC
Duration : Period :
Aimmune Therapeutics Inc Technical Analysis Chart | AIMT | US00900T1079 | 4-Traders
Technical analysis trends AIMMUNE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 59,8 $
Spread / Average Target 106%
EPS Revisions
Managers
NameTitle
Jayson Donald Alexander Dallas President, Chief Executive Officer & Director
Mark D. McDade Chairman
Jeffrey H. Knapp Chief Operating Officer
Eric H. Bjerkholt Chief Financial Officer
Daniel C. Adelman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS INC-22.69%1 720
ABBVIE-2.39%151 404
MERCK KGAA-4.74%12 859
KYOWA HAKKO KIRIN CO LTD-2.97%11 440
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD98.64%11 422
JAZZ PHARMACEUTICALS PLC30.75%10 586